TECregen

About TECregen

TECregen is a Swiss biotechnology company discovering and developing first-in-class therapies that regenerate the thymus, the organ that produces T cells, to restore immune balance and support lifelong immune health. Its mission is to rebuild immunity from within by unlocking the regenerative power of thymopoietics while avoiding the toxicities that have historically limited their therapeutic use, and it believes precision-engineered thymopoietics can redefine how immune decline, cancer and inflammatory disease are treated.

The science starts from the thymus, which acts as the training academy for T cells, teaching them to distinguish invaders and cancer cells from the body's own tissue. It is also one of the most age-sensitive organs: from adolescence, functional thymic tissue is gradually replaced by fat, a process called thymic involution, which reduces production of new naive T cells and contributes to weaker vaccine responses, slower recovery and reduced cancer surveillance in older adults. Thymic damage can also occur earlier through chemotherapy, radiation, stem cell transplantation, severe infection or genetic immune disorders, leaving patients with profound immune depletion.

TECregen integrates advanced ligand engineering, targeted delivery and functional screening to design next-generation thymopoietics that are tissue-targeted, functionally selective and tailored to regenerate thymic epithelial cells and re-establish a T-cell-producing environment. It describes a new class of regenerative biologics that could rejuvenate immune activity, improve disease resistance and speed recovery after immune suppression, and its website presents the team, board, scientific advisory board and investors and partners.

As a venture-backed drug developer, TECregen is bringing its thymus regeneration platform into clinical development for immune decline in aging, cancer and inflammatory or immune-compromised settings, and intends to commercialise its biologics directly or through partnerships. It operates in the regenerative immunology and biologics market.